FDA clears first oral Wegovy pill — first approved oral GLP‑1 for chronic weight management

Obesity drugs just crossed an important line. Wegovy is no longer only a weekly shot — the FDA has now cleared a once-daily tablet version, giving Novo Nordisk the first oral GLP-1 approved in the US for chronic weight management. That sounds like a simple format change, but it isn’t. For a huge number of patients, the gap has been obvious for years: the most effective drugs were injections, and plenty of people either delayed treatment or avoided it entirely because of that. (accessdata.fda.gov) ### What exactly got approved? The new product is a 25 mg Wegovy tablet taken once daily. The FDA label shows it is approved to reduce excess body weight and help maintain weight loss in adults with obesity, or adults with overweight plus at least one weight-related condition. The same label also includes t(accessdata.fda.gov)disease and obesity or overweight. (accessdata.fda.gov) ### Why is a pill a big deal? Because GLP-1 drugs are effective, but injections are a real barrier. Some people hate needles. Some do fine with a weekly pen but never really want to start. And some clinicians have been waiting for something easier to prescribe and easier for patients to accept. A pill does (accessdata.fda.gov)ty treatment. (novonordisk.com) ### How well did the pill work? The key trial here is OASIS 4 — a phase 3 study of oral semaglutide 25 mg in adults with overweight or obesity. In the NEJM paper, oral semaglutide beat placebo on weight loss, and the “if everyone stayed on treatment” estimate landed at about 16.6% mean weight loss. Th(novonordisk.com)le Wegovy, at least on a topline efficacy basis. (nejm.org) ### Is it really the same as injectable Wegovy? Not exactly. Same active ingredient — semaglutide — but different route, different dose, and different day-to-day routine. The shot is once weekly. The tablet is once daily. That matters because convenience cuts both ways: some people will strongly prefer swallowing a pill, but ot(nejm.org)e with specific administration instructions. (accessdata.fda.gov) ### What’s the catch with oral semaglutide? Absorption. Peptide drugs are hard to turn into pills because the stomach and gut are rough on them. Novo Nordisk already proved this trick could work in diabetes with oral semaglutide, but weight management needs higher efficacy, which means the formulation and d(accessdata.fda.gov)easy one. (novonordisk.com) ### Why are people also talking about combos? Because the field is already moving beyond plain GLP-1s. In REDEFINE 1, Novo Nordisk’s cagrilintide-semiglutide combo, CagriSema, produced bigger weight-loss numbers than semaglutide alone, with NEJM reporting significant superiority and company materials (novonordisk.com)“good” obesity treatment may look like a few years from now. (nejm.org) ### Does this connect to liver disease too? Yes — indirectly, but importantly. Doctors care about obesity drugs not only because of the scale number, but because sustained weight loss tends to improve blood sugar, blood pressure, lipids, and liver fat. That is why every strong obesity result now gets read (nejm.org)al does not prove a liver benefit on its own, but it expands a platform that could matter well beyond weight alone. (nejm.org) ### Bottom line This is a format shift with real commercial and clinical weight. Wegovy in a pill will not replace injections overnight — but it makes the GLP-1 category easier to enter, and that alone could change who actually gets treated. (accessdata.fda.gov)